From copy number alterations to structural variants: the evolutionary cascade of papillary renal cell carcinomas
Background Intratumor heterogeneity (ITH) and tumor evolution have been described for
clear cell renal cell carcinomas (ccRCC), but only limited data are available for other kidney …
clear cell renal cell carcinomas (ccRCC), but only limited data are available for other kidney …
[PDF][PDF] Investigating the Role of PTEN in Prostate Cancer Cell-Intrinsic Type I Interferon Responses
N Vitkin - 2018 - qspace.library.queensu.ca
Prostate cancer (PCa) is the most commonly diagnosed cancer in Canadian men and is
characterized by a dysregulated immune response which is influenced by cancer cell …
characterized by a dysregulated immune response which is influenced by cancer cell …
[PDF][PDF] Pharmacological augmentation of heavy ion cancer therapy
N Reppingen - 2018 - tuprints.ulb.tu-darmstadt.de
Tremendous progress is currently achieved in treating cancer, including the fields of
radiother-apy, immunotherapy and pharmacology. Mechanisms of therapy methods on the …
radiother-apy, immunotherapy and pharmacology. Mechanisms of therapy methods on the …
[图书][B] Deletion of C/EBPβ in Oncogenic Ras-Driven Skin Tumors is a Synthetic Lethal Event Promoting p53-Dependent Apoptosis, a Type I Interferon Response, and …
ZJ Messenger - 2018 - search.proquest.com
During tumorigenesis, the developing tumor must overcome a variety of stress phenotypes
such as inflammation, genomic instability, and DNA damage all while sustaining a …
such as inflammation, genomic instability, and DNA damage all while sustaining a …
[PDF][PDF] DNA Hasar Yanıtlarında p53 Tümör Baskılayıcı Proteinin Görevi
M GEZEN, B ERMAN - Turkiye Klinikleri Immunology Allergy …, 2018 - researchgate.net
Kanser vakalarının yüzde ellisinde mutasyona uğrayan tümör baskılayıcı gen TP53
tarafından kodlanan p53 proteini en çok çalışılmış genlerden biridir. Bu protein mutasyona …
tarafından kodlanan p53 proteini en çok çalışılmış genlerden biridir. Bu protein mutasyona …
SGT-53: A Novel Nanomedicine Capable of Augmenting Cancer Immunotherapy
JB Harford, SS Kim, KF Pirollo, A Rait… - Immune Aspects of …, 2018 - api.taylorfrancis.com
Immune Aspects of Biopharmaceuticals and Nanomedicines Page 1 Chapter 30 Immune
Aspects of Biopharmaceuticals and Nanomedicines Edited by Raj Bawa, János Szebeni …
Aspects of Biopharmaceuticals and Nanomedicines Edited by Raj Bawa, János Szebeni …